MicroPort Endovascular MedTech Ltd (688016) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MicroPort Endovascular MedTech Ltd (688016) has a cash flow conversion efficiency ratio of 0.012x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥46.79 Million ≈ $6.85 Million USD) by net assets (CN¥3.98 Billion ≈ $582.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 688016 market cap for the company's overall valuation and market capitalisation.
MicroPort Endovascular MedTech Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how MicroPort Endovascular MedTech Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MicroPort Endovascular MedTech Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MicroPort Endovascular MedTech Ltd ranked by their cash flow conversion efficiency. Explore MicroPort Endovascular MedTech Ltd cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Global Ship Lease Inc
NYSE:GSL
|
0.065x |
|
Anhui Xinhua Media Co Ltd
SHG:601801
|
-0.036x |
|
YFY Inc
TW:1907
|
0.018x |
|
Flight Centre Travel Group Ltd
AU:FLT
|
-0.051x |
|
ICF International Inc
NASDAQ:ICFI
|
0.095x |
|
First Tractor Co Ltd
SHG:601038
|
-0.009x |
|
IGNITIS GRUPE AB EO 2233
F:IGV0
|
0.048x |
|
Pavilion Real Estate Inv Trust
KLSE:5212
|
0.098x |
Annual Cash Flow Conversion Efficiency for MicroPort Endovascular MedTech Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of MicroPort Endovascular MedTech Ltd from 2016 to 2025. View 688016 stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥8.62 Billion ≈ $1.26 Billion |
CN¥573.06 Million ≈ $83.86 Million |
0.066x | -32.01% |
| 2024-12-31 | CN¥3.82 Billion ≈ $559.35 Million |
CN¥373.60 Million ≈ $54.67 Million |
0.098x | -33.89% |
| 2023-12-31 | CN¥3.86 Billion ≈ $565.36 Million |
CN¥571.22 Million ≈ $83.59 Million |
0.148x | -22.81% |
| 2022-12-31 | CN¥1.74 Billion ≈ $255.00 Million |
CN¥333.76 Million ≈ $48.84 Million |
0.192x | -2.91% |
| 2021-12-31 | CN¥1.52 Billion ≈ $222.73 Million |
CN¥300.25 Million ≈ $43.94 Million |
0.197x | +11.95% |
| 2020-12-31 | CN¥1.23 Billion ≈ $180.57 Million |
CN¥217.44 Million ≈ $31.82 Million |
0.176x | +31.17% |
| 2019-12-31 | CN¥1.07 Billion ≈ $155.98 Million |
CN¥143.20 Million ≈ $20.96 Million |
0.134x | -72.82% |
| 2018-12-31 | CN¥216.16 Million ≈ $31.63 Million |
CN¥106.85 Million ≈ $15.64 Million |
0.494x | +34.01% |
| 2017-12-31 | CN¥188.02 Million ≈ $27.51 Million |
CN¥69.36 Million ≈ $10.15 Million |
0.369x | +51.03% |
| 2016-12-31 | CN¥123.38 Million ≈ $18.05 Million |
CN¥30.13 Million ≈ $4.41 Million |
0.244x | -- |
About MicroPort Endovascular MedTech Ltd
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft syste… Read more